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Introduction: Traditional therapies for advanced or metastatic progressive medullary 
thyroid cancer (pMTC) are poor effective. Several TKIs have been tested in clinical 
trials in pMTC patients. 
Areas covered: This paper reviews efficacy and safety of vandetanib in the treatment 
of pMTC. 
Expert Commentary: Vandetanib has been shown to improve progression-free 
survival (30.5 vs 19.3 months in controls) in pMTC patients. Vandetanib is approved 
by FDA and EMA for metastatic MTC in adults; in adolescents and children with 
metastatic or locally advanced MTC, vandetanib seems to be effective. The most 
common adverse events in vandetanib-treated patients are: diarrhea, rash, folliculitis, 
nausea, QTc prolongation, hypertension and fatigue. In patients with aggressive 
differentiated thyroid cancer, vandetanib has shown promising results. Further 
research is needed to determine the ideal targeted therapy, based on tumor molecular 
characterization and host factors, to obtain the best response in terms of survival and 
quality of life. 
 





The most frequent endocrine tumor is thyroid cancer (TC). The main histologic types 
of TC are: a) differentiated TC of follicular origin (DTC): papillary (PTC, 80%), 
follicular (FTC, 11%) and Hürthle cells TC; b) medullary TC (MTC) (developed from 
C cells); c) anaplastic TC (ATC) (2% of all TCs). 
MTC originates from the C cells of the thyroid [that produce calcitonin (CT)]. Most 
cases of MTC are sporadic, and about 25% are hereditary [1].  
MTC is present in 2 forms of multiple endocrine neoplasia MEN2A and MEN2B. 
MEN2A is the most common (50%) type of hereditary MTC, characterized by 
multicentric, bilateral MTC in > 90% of index patients, pheochromocytomas in 50% 
and primary hyperparathyroidism in about 15%. There are three types of MEN2A: a) 
the first is associated with Hirschsprung disease [2]; b) the second is associated with 
cutaneous lichen amyloidosis [3]; c) the third is familial MTC (FMTC) without other 
manifestations.  
MEN2B is about 20% of cases of MEN: MTC is present in 100% of carriers, mucosal 
ganglioneuromas in about 90%, pheochromocytomas in 50%, and a marphanoid 
habitus almost in all. Early identification of MTC in MEN2B is important because 
metastases have been described during the first year of life. 
Activating mutations of the tyrosine kinase (TK) receptor (TKR) RET have been 
described in nearly all hereditary MTC cases and in about 40% of sporadic tumours 
[4].  
RET is a proto-oncogene (mapped to chromosome 10q11.2) encoding for a trans-
membrane TKR, expressed on thyroid C cells [5].  
RET/PTC rearrangements (derived from the fusion of the 3’ portion of the gene to the 
5’ of various genes) induce uncontrolled proliferation by the activation of the 
transcription of RET TK domain [5,6]. RET/PTC rearrangements have been 
evidenced in about 20-40% of sporadic PTC [7], in thyroid adenomas and benign 
lesions [8]. RET/PTC1 derive from the fusion with the CCDC6, and RET/PTC3 from 
the fusion with the NCOA4; these ones are the most frequent among the 13 reported 
RET/PTC rearrangements [9]. 
Ninety-eight% of hereditary MTC and approximately 50% of sporadic MTC show 
activating mutations of RET. Germline gain of function RET mutations have been 
demonstrated in 98% MEN2A families, 85% FMTC and more than 98% MEN2B 
[10].  
Cys-634 mutations are more frequent in MEN2A [4], while M918T and A883F in 
MEN2B [4]. In sporadic MTC, M918T is the most frequent and is linked to a more 
aggressive disease and poorer prognosis [11]. 
In sporadic MTC without RET mutations, other mutations can be responsible for the 
development of MTC, such as somatic H-RAS mutations, which are present in 56% 
of cases, but also KRAS, or rarely NRAS [12].  
Furthermore in MTC, an increased expression of VEGF-A, VEGF-C, VEGFR-1, -2, -
3 are found [13], and particularly, an overexpression of VEGFR-2 correlating with 
metastasis [11]. Several antiangiogenic molecules which block VEGF are studied, but 
often antiangiogenic therapy alone does not induce durable remission [14]. 
MET (Mesenchymal-epithelial transition) is a protoncogene coding for hepatocyte 
growth factor (HGF) receptor (HGFR or c-MET), having TK activity [15]. Mutations 
in c-MET or its overexpression are in several tumors, including MTC. Activated c-
MET stimulates cell reproduction, migration and angiogenesis, while inhibits 
apoptosis; in this way, it leads to tumor progression and metastatic ability [16]. Also, 
mutations in MET pathways have been correlated with poor clinical outcomes and 
drug resistance in patients with cancer [17]. An elevated coexpression of MET and 
HGF has been shown in a subgroup of MTCs [18]. MET has been recently 
investigated as a potential target in the treatment of TC and preliminary clinical 
benefits have been reported [17].  Furthermore,	   overexpression	   of	   EGFR	   in	   some	   MTC	   and	   activation	   of	   the	  mammalian	   target	   of	   rapamycin	   (mTOR)	   intracellular	   signaling	   pathway	   in	  hereditary	  MTC	  have	  been	  shown	  [19].	   	  
However in general it is difficult to evaluate whether a certain protein is 
overexpressed or overactive in MTC since the normal control is lacking.  
The EGFR contributed to activation of RET kinase, growth stimulation and signalling 
[20]. This reinforces the concept that RET may collaborate with diverse transduction 
pathways to promote MTC tumourigenesis and may contribute to activation of other 
as yet unknown cellular signalling cascades [21]. 
Recently, the genomic profiles of two MTCs have been described and the presence of 
a putative oncogenic BRAF fusion has been reported in one of them [22]. 
 
2. MTC therapy 
MTC prognosis depends on tumor size and RET mutations. In fact, it is good for 
patients with MTC confined to the thyroid; however, in 50% of cases, at diagnosis, 
MTC are already metastatic or locally advanced. In these patients there is a worse 
prognosis (10-year survival rate 40%) [23].  
The serum CT (MTC marker) measurement has an important role for an early MTC 
diagnosis, because it has high diagnostic sensitivity and specificity [24].  
In most cases, patients with sporadic MTC have a poorer prognosis because the 
diagnosis is made late; while MEN2A and FMTC are detected early. Three risk levels 
related RET mutations have been reported [25].  
ATA Guidelines recommend in MTC without neck lymph node or distant metastases, 
a total thyroidectomy and dissection of the lymph nodes in the central compartment, 
considering whether to perform the dissection of lymph nodes in the lateral 
compartments according to serum CT levels; while in patients with MTC confined to 
the neck and in cervical lymph nodes, a total thyroidectomy, plus dissection of the 
central lymph node compartment and of the involved lateral neck compartments 
should be performed [26]. C cells do not concentrate iodine, then radioactive iodine 
has no effect on MTC.  
For locally advanced or metastatic progressive MTC, external beam radiotherapy, 
systemic chemotherapy (doxorubicin alone or in association with other agent such as 
5FU and dacarbazine), and other nonsurgical therapies should be evaluated to reach 
tumor control. Chemotherapy treatment in MTC is poor effective. For these reasons, 
the development of new therapies was necessary. 
For recurrent or persistent aggressive MTC, tyrosine kinase inhibitors (TKIs) are 
actually recommended. Recently, several TKIs have been tested in phase I, II, and III 
clinical trials in patients with aggressive MTC but only vandetanib (2011) and 
cabozantinib (2012) have been approved by FDA and EMA [26]. 
 
3. TKIs 
TKIs are molecules that compete with ATP on TKRs, blocking TK activation and the 
oncogenic pathways [27], like RAF, VEGFR, EGFR, MET, platelet-derived growth 
factor receptor (PDGFR), c-KIT, RET kinases. A TKI can block only one TK or 
several TKs (multikinase inhibitor), in fact TKIs have been tested on different cancers 
including TC [27].  
In the last decade, a possible application of axitinib, motesanib, lenvatinib, pazopanib, 
sorafenib, cabozantinib, sunitinib and vandetanib alone or in association have been 
studied in aggressive DTC or MTC, but only a few have been approved [28,29]. 
 
4. Vandetanib 
4.1 Vandetanib synthesis and chemistry, pharmacokinetics and pharmacodynamics 
Vandetanib [IUPAC name: N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-
methylpiperidin-4-yl)methoxy)quinazolin-4-amine)] (trade name CAPRELSA® 
[Vandetanib]) was synthesized through sulfonation, condensation, N-
methylation, nitrification, reduction, cyclization, chlorination and amination, 
and it is an oral once-daily TKI (developed by AstraZeneca), able to block RET, 
VEGFR-2, VEGFR-3 and EGFR and slightly VEGFR-1, that are determinant in 
TC [28]. Vandetanib selectively inhibits VEGFR-2 and VEGFR-3, blocking 
VEGF-stimulated endothelial cell proliferation and migration, and in this way it 
reduces tumor vessel permeability. Moreover, it blocks the activity of EGFR, a 
receptor TK able to mediate tumor cell proliferation, migration and angiogenesis 
[30]. IC50 values of VEGFR-2, VEGFR-3, and EGFR are 40, 110, and 500 nM, 
respectively [31]. A chlorine analogue of vandetanib [chloro-vandetanib, N-(4-
chloro-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-
yl)methoxy)quinazolin-4-amine] has similar or superior biological activities than 
vandetanib [32,33].  
Vandetanib is able to block the enzymatic activity of RET-derived oncoproteins, the 
in vivo phosphorylation and signaling of RET/PTC3 and RET/MEN2B oncoproteins, 
and an EGF-activated EGF-receptor/RET chimeric receptor. It has been shown also 
that vandetanib can inhibit the proliferation of 2 different human PTC cell lines with 
spontaneous RET/PTC1 rearrangements. Moreover, it blocks the formation of tumors 
in vivo upon RET/PTC3-transformed NIH3T3 fibroblasts injection into nude mice 
[34]. 
Vandetanib is also effective on the majority of the mutant oncoproteins (RET/E768D, 
RET/Y791F, RET/S891A, RET/L790F, and RET/A883F), while mutations occurring 
sometimes in MEN2A, substituting valine 804, to leucine or to methionine are 
resistant [35]. 
Moreover, vandetanib could inhibit the growth of a transplantable MTC (derived from 
a sporadic human MTC with the C634R mutation) in nude mice [36]. 
Vandetanib shows an important “indirect” effect on angiogenesis in vivo, as it 
interferes with EGFR-induced production of angiogenic growth factors [31]. 
The vandetanib pharmacokinetics (after a single oral dose) to healthy subjects were 
studied [37].  
Its t½ is of about 10 days after a single oral dose. Food does not significantly interfere 
with the extent of absorption. Over 21 days about two thirds (of the dose) was 
recovered in feces (44%) and in urine (25%). N-desmethyl and N-oxide metabolites 
or unchanged vandetanib were observed in plasma, urine, and feces [37].  
The efficacy and tolerability of vandetanib in TC patients have been investigated in 
many clinical trials (Table 1).  
 
4.2 Overview of the market 
Vandetanib was the first drug approved by FDA (April 2011) for the treatment 
of metastatic MTC in adult patients, ineligible for surgery [38]. Also 
cabozantinib, a small molecule inhibitor of the TKs c-Met and VEGFR-2, able to 
reduce tumor growth and angiogenesis, has been approved by the U.S. FDA for 
MTC [39] and advanced renal cell [40]. Other clinical trials are going on with 
cabozantinib for the treatment of prostate, brain, bladder, ovarian, non-small 
cell lung, melanoma, breast, pancreatic, and hepatocellular carcinomas. 
Vandetanib was evaluated in different clinical trials as a potential treatment for 
non-small-cell lung cancer and promising results were obtained from a phase III 
trial with docetaxel [41]. Another trial with docetaxel was recruiting by July 
2009 [42]. 
 
4.3 Vandetanib clinical trials in adults with MTC   
Two initial studies explored vandetanib in MTC. In the first study, vandetanib 
(300 mg/day) was administered to 30 patients with unresectable, locally 
advanced, or metastatic hereditary MTC [43], 70% of whom with MEN2A. The 
mutated codons were: 634 (in 33% of cases), 618 (27%), 620 (13%), 918 (13%), 791 
(7%), 768 (3%) and 891 (3%). An objective partial response (PR) was obtained in 
20% of cases, and stable disease (SD) in 53%, for a median of 24 weeks with a 
practical adverse event (AE) profile. RET germline mutation and response to 
vandetanib seemed not to have any association [43].  
In the second study, vandetanib had been also administered (100 mg/day or up to 
300 mg/day if disease progressed) to 19 patients with advanced hereditary MTC, 
obtaining also the same data as the preceding study (16% PR, 53% SD, for 24 weeks) 
[44].  
Phase III studies 
The ZETA trial (randomized, double-blind, placebo-controlled multicentre phase III 
trial) was carried out in patients with advanced (5%) or metastatic (95%) MTC [45], 
offered to receive vandetanib [300 mg daily administered until progressive disease 
(PD)] in an open-label phase. Among patients: 10% had hereditary MTC; 90% 
sporadic or unknown origin MTC; 56% had RET mutations; 2% were RET mutation 
negative; and 41% unknown. Patients belonging to the vandetanib group had a 
superior progression-free survival (PFS) vs placebo (30.5 vs 19.3 months; p<0.001), 
while overall survival (OS) was not significantly different (there was a crossover for 
patients with an objective disease progression), CT (69% vs 3%) and 
carcinoembryonic antigen (CEA) (52% vs 2%) response rate were higher (p<0.001). 
Vandetanib was effective in patients with sporadic RET-positive-MTC, and also in 
those with M918T-negative tumors or RET unknown status [45]. 
Considering the efficacy of vandetanib in stabilizing symptomatic and/or PD, it was 
approved in April (FDA) and in November (EU) 2011, to treat unresectable, locally 
advanced or metastatic MTC in patients with symptomatic or PD [46]. 
The efficacy of vandetanib was demonstrated by a retrospective study for the 
treatment of 11 progressive metastatic MTC patients with 36% PR [47].  
Another study was carried out to show the efficacy of vandetanib outside any trial 
[48]. Sixty-eight patients were administered with vandetanib in France from August 
2010 to February 2012. Eight patients were excluded and the results obtained in the 
60 MTC patients were analyzed; 6 had hereditary MTC. Fifty-six (93%) had 
metastatic disease in the mediastinum (82%), bones (65%), liver (53%), or lung 
(53%), and 4 had only locally advanced disease. Median PFS was 16.1 months. 
Twenty-five patients discontinued treatment for disease progression (range 0.3-29 
months). Best tumor response was a complete response in 1 patient, PR in 12 (20%), 
SD in 33 (55%), and progression in 7 (12%). The main adverse events (AEs) were 
skin toxicity, diarrhea, and asthenia; 16 patients (27%) discontinued treatment for 
toxicity, and 1 patient died from vandetanib-induced cardiac toxicity [48].  
Actually, a first phase IV randomized trial is underway to investigate differences in 
response to vandetanib in MTC patients administered with 300 mg vs 150 mg/day 
[49]. 
 
4.4 Vandetanib in pediatric MTC 
In children (5-12 years) and adolescents (13-18 years) with metastatic or locally 
advanced MTC, a phase I/II trial has been carried out. Vandetanib 100 mg/m(2)/d was 
administered to 16 patients, and the authors concluded that this dose is well-tolerated, 
and strongly effective for adolescents and children with locally advanced or 
metastatic MTC and MEN2B [50].  
More recently a child with advanced, metastatic, MTC associated with MEN2B has 
been described who showed a response to vandetanib with a fall in CT levels and a 
reduction in size of the thyroid malignancy, lymph nodes, and pulmonary metastases, 
with a SD for about 4 years [51]. 
These studies suggest that vandetanib can be used for the treatment of pediatric 
patients with MTC. 
 
4.5 Vandetanib in ectopic Cushing syndrome by MTC  
MTC may rarely presents with paraneoplastic syndrome and ectopic Cushing 
syndrome (ECS). Bilateral adrenalectomy is often required to manage this situation. 
The regression of ECS was first observed in a patient with MTC treated with 
vandetanib [52].  
A subsequent study described a 17-year-old adolescent with metastatic MTC and 
associated ACTH-dependent ECS (in the context of MEN2B), who showed a rapid 
decrease in serum cortisol and improvement of clinical symptoms when treated with 
vandetanib [53].  
Recently, a patient with sporadic advanced MTC with lymph node and liver 
metastases, that after 16 years of follow-up developed an ECS was treated with 300 
mg/day vandetanib. After one month a biochemical and clinical response of the ECS 
was achieved but without a significant reduction of tumor [54]. These studies suggest 
that vandetanib can be used for the medical treatment of MTC patients with ECS.   
 
4.6 CT, CEA, miRNA for monitoring vandetanib treatment 
The first two phase II trials [35,36] of vandetanib in MTC evidenced a high decrease 
(≥50%) in CEA and CT levels. CT was not associated with tumor growth inhibition, 
while CEA was hypothesized to be a more accurate marker of tumor response to 
vandetanib. 
However, to evaluate the role of CEA and CT for treatment monitoring and the 
decision-making process, 21 patients with progressive MTC receiving vandetanib 
(300 mg orally per day) were studied [55]. Tumor restaging was performed every 3 
months by computed tomography. Furthermore, CEA and CT were measured at the 
day of computed tomography imaging. During long-term follow-up [range, 97-1140 
days], CT and CEA initially declined in 71.4% and 61.9% of patients, followed by 
fluctuations. A rise in CT ≥40% between 2 subsequent measurements was associated 
with a PD (71% sensitivity, 83% specificity, and 82% accuracy). Fluctuations in CEA 
circulating levels were not associated with PD. These data suggest a significant rise in 
CT ≥40% might be an early indicator of PD [55]. 
Further studies are needed to elucidate the role of CT and CEA circulating levels 
determination for treatment monitoring and the decision-making process of MTC 
patients treated with vandetanib. 
More recently, a study evaluated the strongest up-regulated miRNA in MTC samples, 
miR-375 [56]. It was shown that miR-375 overexpression was associated with 
decreased cell proliferation and synergistically increased sensitivity to vandetanib. 
The combination of increased expression of miR-375 and decreased expression of 
SEC23A points to sensitivity to vandetanib, suggesting the expression levels of miR-
375 and SEC23A should be evaluated as an indicator of eligibility for treatment with 
vandetanib of MTC patients [56]. 
 
4.7	  Vandetanib in aggressive DTC 
Leboullex et al. [57] conducted a double-blind phase II, randomized trial, in 145 
patients with metastatic or locally advanced DTC [PTC, FTC, or poorly differentiated 
(PDTC)] on the efficacy of vandetanib (300 mg/day) vs placebo. In patients belonging 
to the vandetanib group vs placebo, PFS (primary endpoint) was 11.1 months vs 5.9 
months, PR 8% vs 5%, and SD 57% vs 42%. PTC than FTC and PDTC showed better 
results [57].  
Currently, a new randomized, double-blind, placebo-controlled, multi-centre phase III 
study is underway in aggressive DTC patients [58]. 
 
5. Safety and tolerability  
Vandetanib treatment may cause different AEs but it is generally tolerable as AEs are 
usually mild. The most common AEs are diarrhea, hypertension, QTc prolongation 
and fatigue (of at least grade 3), but also nausea, headache, rash and folliculitis, 
reduced appetite and acne [43-45, 50, 57].  
The half-life of vandetanib is 19 days, and this is to be noticed in the management of 
AEs [59,60]. AEs grade 1 or 2 may improve if the dose is reduced, while in case of 
AEs grade 3 or 4, it is recommendable to stop the treatment with vandetanib until AEs 
resolve, then the drug might be taken up again but at a lower dose [44]. 
 
5.1 Dermatological AEs 
The ZETA trial showed that dermatological AEs were present in 45% of patients [45]. 
Among EGFR inhibitors, vandetanib often causes a papulopustular eruption, owing to 
EGFR inhibition, as EGFRs are highly expressed in epidermis and its appendages 
[61], leading to hyperkeratosis, follicle obstruction and inflammation of the pilo-
sebaceous follicle [61].  
The reported incidence of all-grade and high-grade rash was 46.1% and 3.5% in 2961 
MTC patients administered with vandetanib [62].  
Photosensitivity (always present), xerosis, finger clefts, paronychia, genital skin 
reactions, hair changes, subungual splinter hermorrhages and blue-dots are other 
vandetanib-associated dermatological AEs [61]. 
Photoallergic dermatitis has been described in patients treated with vandetanib, that  
could be treated by discontinuation of the drug, and supportive care including topical 
and oral steroid administration [63].  
Mucositis, erythrodysesthesia, pruritus are AEs less frequent, and 1 case of Stevens-
Johnson syndrome has been reported [64].  
Dermatological AEs in children administered with target anticancer drugs (as 
vandetanib) are quite the same as in adults [65]. 
Dermatological AEs are simply treatable, but owing to their high incidence, their 
prevention and early management are determinant to decrease the risk to reduce the 
dosage or interrupt it.  
 
5.2 Gastrointestinal AEs 
A recent meta-analysis has evaluated the relative risk and incidence of gastrointestinal 
AEs during vandetanib in patients with cancer. Twenty-two trials with 6382 patients 
were evaluated, summarizing incidences of all-grade gastrointestinal AEs in patients 
with cancer were anorexia 24%, constipation 17%, diarrhea 46%, nausea 29%, and 
vomiting 17% [66].  
In the ZETA trial, the most common gastrointestinal AE is diarrhea (56% of patients), 
then nausea (33%), reduced appetite (21%), vomiting (14%) and abdominal pain 
(14%) [45]. These AEs (particularly diarrhea) often lead to poor patient compliance 
and interruption of the therapy. Patient education with dietary measures is 
determinant. 	  
The increased hormone production by MTC may accelerate intestinal transit, causing 
diarrhea; for this reason, it improves with vandetanib. Diarrhea often depends on the 
treatment with vandetanib and its therapy is based on correct hydration and possibly 
loperamide.	  
To treat nausea it is not recommended the use of 5-HT3 antagonists (ondansetron) for 
the risk of prolongation QTc interval [67], and it is also necessary to administer 
metoclopramide prudently. In the antiemetic therapy, another option is palonosetron 
[68]. 	  
In the case of severe gastrointestinal AEs, vandetanib shoud be interrupted upon the 
improvement of the symptoms. 
 
5.3 Cardiovascular AEs  
Cardiovascular AEs are associated with vandetanib, as hypertension, bleeding, 
ventricular dysfunction, arterial thrombosis, fatal cardiac failure and QTc interval 
prolongation [69,70].  
The incidences of all-grade and high-grade hypertension have been evaluated 
in 3154 patients, showing to be 24.2% [95% confidence interval (CI), 18.1-
30.2%] and 6.4% (95% CI, 3.3-9.5%) [71]. All-grade hypertension had a more 
significant incidence in MTC patients than in the others [71]. For this reason, 
an appropriate blood pressure monitoring and treatment with ACE inhibitors (if 
needed) are recommendable in vandetanib-treated subjects. Calcium antagonist 
and beta blockers can be administered if blood pressure is uncontrolled.  
The case of a patient with metastatic MTC who presented a favorable response to 
vandetanib therapy, who developed after 14 months of therapy a fatal cardiac failure 
has been described. Postmortem examination of the heart marked myocyte 
degeneration in the subendocardial zones and papillary muscles of the myocardium 
suggestive of drug-induced cardiotoxicity [69]. 
Also in the study by Chougnet et al. 1 patient died from vandetanib-induced cardiac 
toxicity [48]. 
QTc prolongation is a determinant cardiological AE associated wth vandetanib (and 
TKIs therapy). In the ZETA trial, QTc >500 ms was reported in 14% of patients 
administered with vandetanib; 2 cases of death in patients with QTc >550 ms have 
been shown (1 caused by sepsis and 1 to heart failure) [60].  
Earlier than the beginning of vandetanib, ECG and echocardiogram are highly 
suggested and the treatment had not be done in the case of QTc >450 ms (US) or 
>480 ms (EU). During the treatment with vandetanib, drugs prolonging QTc interval 
should not be administered. Electrolyte and circulating TSH levels should be kept 
within the normal interval. QTc interval prolongation is quite slight at clinical 
dosages, not leading to significant morbidity clinically [70], though owing to the 
potential for QT prolongation, torsades de pointes, and sudden death, vandetanib is 
limited through a Risk Evaluations and Mitigation Strategy program [46].  
 
5.4 Thyroid dysfunctions 
Thyroid dysfuctions are reported in patients treated with vandetanib [72]. 
Thyroid function was studied in 19 patients treated with vandetanib (100 mg) for 
locally advanced or metastatic hereditary MTC [44]. All 19 patients receiving 
vandetanib had undergone prior thyroidectomy and were receiving thyroid hormone 
replacement before entering the study. Baseline TSH data were available for 17 
patients, and in these patients TSH levels increased [5.1-fold (mean) and 7.3-fold 
(median) increases over baseline]. No patients were reported to have symptomatic 
hypothyroidism, but thyroid hormone replacement therapy was increased in 2 patients 
[44]. 
The pattern of thyroid hormones levels was studied in 13 pediatric patients with MEN 
2B and MTC (median age 13.0) [73].	   Eleven patients (85%) had undergone prior 
thyroidectomy and received single-drug therapy with vandetanib for >6 months. 
While on vandetanib treatment, all 11 athyerotic patients had significantly increased 
circulating TSH, after a median time to reach the initial peak of elevated TSH of 
1.8 months (0.3 - 9.3). An increase of levothyroxine	  (LT4) dosage was observed from 
a baseline of 91 mcg/m(2)/day (±24) to 116 mcg/m(2)/day. For the 2 patients with 
intact thyroid glands, free T4 and TSH remained normal. It was suggested that an 
indirect effect of vandetanib on the metabolism of thyroid hormone, or an altered TSH 
sensitivity at the pituitary could cause elevated TSH levels in athyreotic patients. A 
correct recognition and management of abnormal thyroid hormone levels is 
determinant in growing children on TKIs. This study suggests that pediatric athyreotic 
MTC patients during the first few months of vandetanib therapy necessitate an 
increase in LT4 dose [73].  
 
5.5 Other AEs 
Fatigue, headache, hypocalcemia, hypoglycemia, and increased transaminase levels 
are other frequent side effects [72]. 
 
6. Limits and drug resistance	  
TKIs therapy is not toxic as chemotherapy, but severe AEs need interrumption of the 
treatment. Moreover, TKIs stop tumor growth but can not remove it. The reported 
discordant results by clinical trials about the efficacy of TKIs in aggressive DTC 
patients perhaps are caused by mechanisms of drug resistance, activating different 
mitogenic signals [74]. Combining TKIs targeting different pathways is now under 
evaluation. 
Mechanisms of primary and acquired resistance to vandetanib have been 
evaluated. The presence of RET mutations is not suitable to predict clinically the 
response to the treatment in MTC [75].	   The clinical efficacy of vandetanib has 
been confirmed by ZETA trial in patients with sporadic MTC with M918T 
mutation. The rare RET V804M and V804L mutations occurring in sporadic 
and hereditary MTC confer resistance to vandetanib [35], as shown in in vitro 
studies, leading clinically to primary or acquired resistance. Sorafenib is effective 
against the V804 mutant in vitro [76]. 
Further research is necessary to investigate whether Ras mutations, present in 60-80% 
of RET-negative sporadic MTC [12], may lead to clinical resistance to vandetanib. 
Anyway, in vitro cell lines with acquired resistance to vandetanib have a constant 
activation of the Ras/Raf/MEK pathway (that sorafenib is able to abolish) [77].  
The evaluation of the sensitivity of TC cells to TKIs could improve the response to 
treatment, as in vitro drug screening with human primary tumor cells has a 60% 
positive predictive and a 90% negative predictive value of clinical response in vivo in 
the same patient. This could permit not to administer inactive drugs to patients 
[78,79]. Moreover, primary TC cell cultures from anaplastic thyroid cancer (ANA) 
can be established from fine-needle aspiration giving the possibility to test in these 
cells the chemosensitivity to different drugs in each patient (avoiding useless surgical 
biopsies, used till nowadays to establish ANA) [79-83].  	  
7. Combination studies 
The synergic activity of various antineoplastic drugs in combination studies have been 
investigated [84]. 
A synergic inhibition of tumor growth has been reported combining treatment with 
bortezomib (proteasome inhibitor), and EGFR inhibitors (gefitinib, vandetanib, 
cetuximab), in EGFR-expressing human cancer cell lines [85]. A not randomized, 
phase I/II trial on vandetanib with bortezomib is recruiting patients with solid tumors 
(as MTC) [86]. 
The synergic activity of vandetanib plus irinotecan has been also investigated. 
Vandetanib inhibits tumor growth in vitro, as shown by preclinical data, in a 
sequence-dependent manner with chemotherapeutic agents, as irinotecan in colon 
cancer cell lines [87]. Another paper evaluated the combination with irinotecan in a 
murine xenograft model of vandetanib-treated human colon cancer, showing an 
additional synergic activity of these drugs [88].  
The response to vandetanib, radiotherapy and irinotecan was investigated in human 
LoVo colorectal tumoral cells, reporting an increased antineoplastic effects of 
irinotecan and radiation if administered with vandetanib, leading to a decreased tumor 
growth [89]. 
Many papers have reported that the PI3K/Akt/mTOR signaling pathway is involved in 
the pathogenesis and progression of neuroendocrine tumors and MTC, as it seems that 
the deregulation of such a pathway contributes to the tumorigenic effect of RET 
mutations. A possible effective therapeutic option in patients with advanced MTCs 




Vandetanib has been shown to improve PFS (30.5 vs 19.3 months in the placebo 
group) in patients with MTC. Patients with sporadic RET-positive-MTC took 
advantages from vandetanib and a good response was also shown in those with 
M918T-negative tumors or RET unknown status. Vandetanib was approved in 2011 
by FDA for metastatic MTC and in 2012 by EMA.  
Also in adolescents and children with metastatic or locally advanced MTC, 
vandetanib is well-tolerated, and seems to be effective. The regression of ECS has 
been observed in MTC patients treated with vandetanib, too. 
Further studies are required to elucidate the role of CT and CEA circulating levels 
determination for treatment monitoring and the decision-making process of MTC 
patients treated with vandetanib. 
Diarrhea, QTc prolongation, hypertension and fatigue, headache, rash and folliculitis, 
nausea, reduced appetite and acne are the most common AEs associated to vandetanib 
treatment. AEs grade 1 or 2 may improve if the dose is reduced, while in case of AEs 
grade 3 or 4, it is recommendable to stop the treatment with vandetanib until AEs 
resolve, then it might be taken up again but at a lower dose. 
To increase the antineoplastic effect of vandetanib, and to overcome the appearance 
of drug resistance, combination studies with other anticancer agents are on-going. To 
personalize the TKIs therapy in each patient with MTC or aggressive DTC, attempts 
have been made on the basis of the molecular characterization of the tumor. More 
recently, it has been suggested the possibility to evaluate the sensitivity in vitro of 
primary aggressive DTC or MTC cells from each subject to different TKIs to 
ameliorate the effectiveness of the treatment, preventing the administration of inactive 
drugs, potentially dangerous, to these patients. 
In conclusion, vandetanib has been shown to exert an important therapeutic effect in 
patients with MTC improving PFS. In aggressive DTC patients vandetanib has shown 
promising results, and a phase III trial is on-going. 
Further studies are necessary to establish the ideal targeted therapy, considering the 
molecular characterization of the tumor and host factors, in order to improve survival 
and quality of life. 
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Expert commentary 
Vandetanib (trade name CAPRELSA® [Vandetanib]) is an oral once-daily TKI, able 
to block RET, VEGFR-2, VEGFR-3 and EGFR and slightly VEGFR-1, that are 
determinant in medullary thyroid cancer (MTC).  
It was shown that vandetanib could inhibit the growth of a transplantable MTC 
(derived from a sporadic human MTC with the C634R mutation) in nude mice. 
Vandetanib shows an important “indirect” effect on angiogenesis in vivo, as it 
interferes with EGFR-induced production of angiogenic growth factors. 
In a phase III clinical study, vandetanib improved progression-free survival (PFS) 
(30.5 vs 19.3 months in the placebo group) of patients with MTC. Patients with 
sporadic RET-positive-MTC took advantages from vandetanib and a good response 
was also shown in those with M918T-negative tumors or RET unknown status. 
Recently, a phase I/II trial has been conducted for adolescents and children (5-12 
years) with metastatic or locally advanced MTC, showing that treatment with 
vandetanib 100 mg/m(2)/d, is well-tolerated, and strongly effective. 
The regression of ectopic Cushing syndrome was observed in MTC patients treated 
with vandetanib.  
Vandetanib was approved in 2011 by FDA for metastatic MTC and in 2012 by EMA.  
The most frequent adverse events (AEs) in vandetanib-treated patients are: diarrhea, 
rash and folliculitis, nausea, QTc prolongation, hypertension and fatigue, headache, 
decreased appetite and acne. AEs	  grade	  1	  or	  2	  may	  improve	  if	  the	  dose	  is	  reduced,	  while	  in	  case	  of	  AEs	  grade	  3	  or	  4,	  it	  is	  recommendable	  to	  stop	  the	  treatment	  with	  vandetanib	  until	  AEs	  resolve,	  then	  it	  might	  be	  taken	  up	  again	  but	  at	  a	  lower	  dose. 
In a phase II clinical study, vandetanib improved PFS (11.1 months vs 5.9 months 
months in the placebo group) of patients with aggressive differentiated thyroid cancer 
(DTC). 
In conclusion, vandetanib has been shown to exert an important therapeutic effect in 
patients with MTC improving PFS. In aggressive DTC patients vandetanib has shown 




Five-year view  
Patients with familial, or sporadic MTC (with different RET mutations) will be 
treated with vandetanib, to evaluate a possible predictive role of these mutations to the 
response to therapy.   
Further studies are needed to elucidate the role of calcitonin and CEA circulating 
levels determination for treatment monitoring and the decision-making process of 
MTC patients treated with vandetanib. 
In aggressive DTC patients, vandetanib has shown promising results, suggesting that 
in the next future it will be an alternative to sorafenib in these patients. 
To increase the antineoplastic effect of vandetanib, and to overcome the appearance 
of drug resistance, combination studies with other anticancer agents are on-going. To 
personalize the TKIs therapy in each patient with MTC or aggressive DTC, attempts 
have been made on the basis of the molecular characterization of the tumor. More 
recently, it has been suggested the possibility to evaluate the sensitivity in vitro of 
primary aggressive DTC or MTC cells from each subject to different TKIs to 
ameliorate the effectiveness of the treatment, preventing the administration of inactive 
drugs, potentially dangerous, to these patients. 
Further studies are necessary to establish the ideal targeted therapy, considering the 
molecular characterization of the tumor and host factors, in order to improve survival 
and quality of life. 
  
Key issues:  
1- Vandetanib (trade name CAPRELSA® [Vandetanib]) is an oral once-daily TKI, 
able to block RET, VEGFR-2, VEGFR-3 and EGFR and slightly VEGFR-1, that are 
determinant in MTC. 
2- It was shown that vandetanib could inhibit the growth of a transplantable MTC 
(derived from a sporadic human MTC with the C634R mutation) in nude mice. 
Vandetanib shows an important “indirect” effect on angiogenesis in vivo, as it 
interferes with EGFR-induced production of angiogenic growth factors. 
3- In a phase III clinical study, vandetanib improved progression-free survival (PFS) 
(30.5 vs 19.3 months in the placebo group) of patients with MTC. Patients with 
sporadic RET-positive-MTC took advantages from vandetanib and a good response 
was also shown in patients with M918T-negative tumors or RET unknown status. 
4- Recently, a phase I/II trial has been conducted for adolescents and children (5-12 
years) with metastatic or locally advanced MTC, showing that treatment with 
vandetanib 100 mg/m(2)/d is well-tolerated, and strongly effective. 
5- Vandetanib was approved in 2011 by FDA for metastatic MTC and in 2012 by 
EMA.  
6- The most frequent AEs in vandetanib-treated patients are: diarrhea, rash and 
folliculitis, nausea, QTc prolongation, hypertension and fatigue, headache, decreased 
appetite and acne. AEs	  grade	  1	  or	  2	  may	  improve	  if	   the	  dose	  is	  reduced,	  while	   in	  case	   of	   AEs	   grade	   3	   or	   4,	   it	   is	   recommendable	   to	   stop	   the	   treatment	   with	  vandetanib	  until	  AEs	  resolve,	  then	  the	  therapy	  might	  be	  taken	  up	  again	  but	  at	  a	  lower	  dose.	  
7- Further studies are needed to elucidate the role of calcitonin and CEA circulating 
levels determination for treatment monitoring and the decision-making process of 
MTC patients treated with vandetanib. 
8- In aggressive DTC patients, vandetanib has shown promising results, suggesting 
that in the next future it will be an alternative to sorafenib in these patients. 
9- To increase the antineoplastic effect of vandetanib, and to overcome the 
appearance of drug resistance, combination studies with other anticancer agents are 
on-going. To personalize the TKIs therapy in each patient with MTC or aggressive 
DTC, attempts have been made on the basis of the molecular characterization of the 
tumor. More recently, it has been suggested the possibility to evaluate the sensitivity 
in vitro of primary aggressive DTC or MTC cells from each subject to different TKIs 
to ameliorate the effectiveness of the treatment, preventing the administration of 
inactive drugs, potentially dangerous, to these patients. 
10- Further studies are necessary to establish the ideal targeted therapy, considering 
the molecular characterization of the tumor and host factors, in order to improve 




Most important related websites: 
European Thyroid Association (ETA): http://www.eurothyroid.com/ 
American Thyroid Association (ATA): http://www.thyroid.org/ 
 




cancer PR SD PD PFS 
(months) 
Wells et al.43 30 MTC 20% 53% 3% 27.9 
Robinson et al.44 19 MTC 16% 53% 16% 5.6 
Wells et al.45 231 MTC 45% 42% / / 
Chougnet et al.48 60 MTC 20% 55% 12% 16.1 
Fox et al.50 16 MTC 
pediatric MEN2B 
47% / / / 
Medullary thyroid cancer (MTC); partial response (PR); progressive 
disease (PD); progression-free survival (PFS); stable disease (SD). 
 
 
